Irisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia
Open Access
- 21 October 2025
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 14 (10) , 1268
Abstract
Irisin and brain-derived neurotrophic factor (BDNF) are considered potential biomarkers for sarcopenia; however, their interplay and relationship with oxidative stress remain unclear. Therefore, the aim of this study was to assess the serum concentration of irisin and BDNF in patients over 60 years of age, as well as their relationship with dynapenia and redox homeostasis. Dynapenia was diagnosed using the Five Times Sit-to-Stand Test (5TSST). Serum levels of irisin, BDNF, total oxidative status (TOS), and total antioxidative status (TAS) were measured, and the oxidative stress index (OSI) was calculated. A total of 110 patients from a geriatric ward (72.7% women, mean age 78.2 ± 7.1 years) participated in the study. BDNF concentration was negatively associated with dynapenia, irisin, and the irisin/BDNF ratio. TOS, TAS, and OSI were negatively associated with BDNF and positively associated with irisin and dynapenia. No significant association was found between irisin and sarcopenia parameters. In regression analysis, significantly higher odds of dynapenia were observed for older age, female sex, a greater number of chronic diseases, and higher OSI values, after adjusting for TOS, BDNF, and the irisin-to-BDNF ratio. These results confirm redox imbalance as an independent predictor of sarcopenia. A lower BDNF concentration and a higher irisin-to-BDNF ratio may indicate a protective role of BDNF in the development of sarcopenia in geriatric patients; however, this finding requires further confirmation.Keywords
Funding Information
- Uniwersytet Medyczny w Bialymstoku (B.SUB.25.268)
This publication has 51 references indexed in Scilit:
- Low five-repetition chair stand test and usual gait speed scores predict falls within one year in an outpatient clinic for frailtyEuropean Geriatric Medicine, 2025
- Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and AgingCalcified Tissue International, 2023
- Handgrip strength measurement protocols for all-cause and cause-specific mortality outcomes in more than 3 million participants: A systematic review and meta-regression analysisClinical Nutrition, 2022
- Serum irisin level is independent of sarcopenia and related muscle parameters in older adultsExperimental Gerontology, 2022
- The Effects of Exercise Training on the Brain-Derived Neurotrophic Factor (BDNF) in the Patients with Type 2 Diabetes: A Systematic Review of the Randomized Controlled TrialsJournal of Diabetes & Metabolic Disorders, 2020
- The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal womenEndocrine, 2018
- SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomesJournal of Cachexia, Sarcopenia and Muscle, 2015
- Exercise Induces Hippocampal BDNF through a PGC-1α/FNDC5 PathwayCell Metabolism, 2013
- Physical exercise modulates peripheral levels of brain-derived neurotrophic factor (BDNF): A systematic review of experimental studies in the elderlyArchives of Gerontology and Geriatrics, 2013
- A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cationClinical Biochemistry, 2004